A European access model is gaining attention for how CAR-T therapies could reach more patients outside major centers. The University of Barcelona described a not-for-profit, hospital-exemption manufacturing approach aimed at increasing availability of CAR-T cell therapy, citing low national access rates even in countries where therapies are approved. The program, using the Spanish regulatory “hospital exemption,” is developing ARI-0001, a CD19-targeted second-generation CAR T-cell therapy currently in clinical pilot trials (NCT07412405). The effort aims to support local delivery and production to shorten time-to-treatment and address capacity constraints. The presentation also noted longer-term ambitions for allogeneic “off-the-shelf” CAR-T platforms, positioning autologous manufacturing as a bridge toward broader supply. For payers and developers, the strategy underscores how manufacturing footprint, regulatory flexibility, and logistics can shape real-world access independent of trial efficacy signals.